Mast cell activation: beyond histamine and tryptase.
brain fog
comorbidities
diagnosis
inflammatory mediators
mast cells
mastocytosis
mechanism
treatment
Journal
Expert review of clinical immunology
ISSN: 1744-8409
Titre abrégé: Expert Rev Clin Immunol
Pays: England
ID NLM: 101271248
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
medline:
23
5
2023
pubmed:
9
4
2023
entrez:
8
4
2023
Statut:
ppublish
Résumé
Mast cells are found in all tissues and express numerous surface receptors allowing them to sense and respond to allergic, autoimmune, environmental, neurohormonal, pathogenic and stress triggers. Stimulated mast cells are typically called 'activated' but the mechanisms involved and the mediators released can vary considerably. Mast cell activation diseases (MCADs) include primary, secondary and idiopathic conditions, especially mast cell activation syndrome (MCAS), but mast cells are activated in many other disorders making the diagnosis and treatment challenging. Mast cells can release numerous biologically active mediators, some of which are prestored in secretory granules while others are newly synthesized and released without degranulation. Most of the emphasis has so far been on secretion of histamine and tryptase, which do not explain all the multisystemic symptoms experienced by patients with MCADs. As a result, drug development has focused on antiproliferative therapy or blocking the action of individual mediators and not on inhibitors of mast cell activation. Activated mast cells are involved in the pathogenesis of MCADs, but also in other disorders making appropriate diagnosis and treatment challenging. The definition of mast cell activation should be expanded beyond histamine and tryptase, with an emphasis on better detection and treatments.
Identifiants
pubmed: 37029958
doi: 10.1080/1744666X.2023.2200936
doi:
Substances chimiques
Histamine
820484N8I3
Tryptases
EC 3.4.21.59
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM